EPSRC Centre for Doctoral Training in Advanced Therapeutics and Nanomedicines

 
University of Nottingham
  

Our History

 

Our-history--long-photo-web

  • In 2005, the University of Nottingham's School of Pharmacy was awarded £2.5 million for a centre of excellence in Targeted Therapeutics. Funded by AstraZeneca and the Engineering and Physical Sciences Research Council (EPSRC), this was the first Centre for Doctoral Training (CDT) to be established in direct collaboration with an industry partner. 
  • In 2012 the CDT expanded as the University of Nottingham and AstraZeneca were joined in partnership by University College London’s School of Pharmacy and five additional industry partners: Boots, Pfizer, GlaxoSmithKline, Quotient Clinical, and Molecular Profiles.
  • In October 2014, together with industrial partners, we launched the CDT in Advanced Therapeutics & Nanomedicines, welcoming 12 new PhD students, 6 each based at Nottingham and UCL. In 2016, Quotient Sciences, Croda and Evonik joined the CDT as partners.

Find out more about the governance of the CDT. 

EPSRC Centres for Doctoral Training in Advanced Therapeutics and Nanomedicines

 

The University of Nottingham
School of Pharmacy
Boots Science Building
University of Nottingham,
Nottingham, NG7 2RD
t: +44(0)7809 888378
e: Graham.Harrison@nottingham.ac.uk

University College London
School of Pharmacy
University College London
29-39 Brunswick Square,
London WC1N 1AX.
t: +44 (0) 20 3987 28811
e: s.marks.pharm@ucl.ac.uk